Speaking with David Van Sickle, CEO, Propeller Health
David Van Sickle, CEO, Propeller Health, talks with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event about how the digital therapeutics landscape has changed.
David Van Sickle, CEO, Propeller Health, talks with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event about how the digital therapeutics landscape has changed.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
